Exelixis, Inc. Investigation
Company: Exelixis, Inc.
Ticker: (NASDAQ) EXEL
How to Check Whether You May Be Eligible in the Exelixis, Inc. Investigation
Investigation Details
Exelixis shares dropped in after-hours trading after the Company reported Q2 revenue of approximately $628.7 million, missing consensus estimates, and lowered and narrowed its full-year 2026 revenue outlook.
The revenue shortfall came alongside an adjusted EPS beat of $0.91 per share. Investors sold on the top-line number. The Company attributed the reduced full-year outlook to a slower-than-expected ramp in its neuroendocrine-tumor business -- a franchise Exelixis had described to investors as a market-leading position for CABOMETYX in the oral second-line plus segment.
The May 5, 2026 first quarter earnings call, Chief Financial Officer Christopher Senner stated: "Finally, we are reiterating our full year 2026 financial guidance." That guidance was subsequently lowered.